Downstream coronary effects of drug-eluting stents Richard A. Krasuski, MD, George M. Cater, MSE, Ganesh P. Devendra, MD, Kathy Wolski, MPH, Mehdi H. Shishehbor, DO, MPH, Steven E. Nissen, MD, Carlos Oberti, MD, Stephen G. Ellis, MD American Heart Journal Volume 162, Issue 4, Pages 764-771.e1 (October 2011) DOI: 10.1016/j.ahj.2011.08.001 Copyright © 2011 Mosby, Inc. Terms and Conditions
Figure 1 Cohort identification and selection. American Heart Journal 2011 162, 764-771.e1DOI: (10.1016/j.ahj.2011.08.001) Copyright © 2011 Mosby, Inc. Terms and Conditions
Figure 2 Kaplan-Meier analysis of new lesion development in control and target vessels for both the entire (A) and the propensity-matched (B) cohorts. American Heart Journal 2011 162, 764-771.e1DOI: (10.1016/j.ahj.2011.08.001) Copyright © 2011 Mosby, Inc. Terms and Conditions
Figure 3 Kaplan-Meier analysis of new interventions in control and target vessels for both the entire (A) and the propensity-matched (B) cohorts. American Heart Journal 2011 162, 764-771.e1DOI: (10.1016/j.ahj.2011.08.001) Copyright © 2011 Mosby, Inc. Terms and Conditions
Supplementary Figure 1 Downstream Vessel Determination. American Heart Journal 2011 162, 764-771.e1DOI: (10.1016/j.ahj.2011.08.001) Copyright © 2011 Mosby, Inc. Terms and Conditions